Peerwise Medical, Corp.

### Executive Summary Peerwise Medical, Corp., a Delaware corporation incorporated in 2023, has raised $5.0M in a Regulation D private placement as of May 20, 2026. The offering is classified under 'Other Technology' and involves equity securities, with no debt or pooled investment fund interests indicated. The filing lists Natalia Khosla and Rachel O'Driscoll as executive officers and directors, but does not disclose the number of investors, whether any are non-accredited, or the minimum investment accepted. The absence of an exemption rule (506(b) or 506(c)) in the provided XML excerpt limits further structural detail, but the $5.0M raise signals early-stage capital deployment in the healthcare technology space. ### Investor Edge Watch for an amended Form D (D/A) which would reveal changes in offering terms, additional investors, or a larger raise. Also monitor for any subsequent patent filings or FDA-related announcements from Peerwise Medical, as these would validate the technology and potentially attract strategic partners. ### Sector capital positioning This $5.0M raise in the 'Other Technology' sector reflects continued private capital flow into early-stage health-tech ventures, particularly those leveraging digital or platform-based models. The modest size suggests a seed or Series A round, aligning with current trends where investors are selectively backing capital-efficient startups in medical technology. ### Convergence Signals No direct convergence signals (patents, government contracts, or legislation) are evident from the filing. However, the company's New York address and incorporation in Delaware are standard for startups. The involvement of two female executives may align with broader diversity-focused investment trends, but this is speculative. ### Key Takeaways - Peerwise Medical raised $5.0M in private equity under Regulation D, with first sale on May 20, 2026. - The filing lists Natalia Khosla and Rachel O'Driscoll as executive officers and directors, but no external investors are named. - The 'Other Technology' classification and $5.0M amount suggest an early-stage health-tech company, likely pre-revenue. ### Risk Indicators & Flags The filing lacks critical details such as the specific exemption rule (506(b) or 506(c)), total number of investors, and whether any non-accredited investors participated. This opacity could indicate a small, insider-led round or incomplete disclosure. Additionally, the company is very young (incorporated in 2023), increasing execution risk. ### Verification & References All data is directly from the SEC Form D filing (Accession Number 000213791226000001). The company's CIK (0002137912) and EDGAR URL are provided. The $5.0M raised, date of first sale (2026-05-20), and officer/director names are verifiable. The exemption rule and investor count are not available in the provided excerpt.